Cutaneous Inflammation
Conditions
Brief summary
The objective of this exploratory study is to gain an understanding of cutaneous and systemic inflammation and how restoration of the skin barrier through the use of moisturizer may restore the skin barrier function and reduce systemic inflammation in elderly humans compared to the young. The exploratory study will consist of three visits per subject. Subjects will be instructed to apply a moisturizer (Vanicream Moisturizing Skin Cream) over the entire skin surface from the neck down twice daily for up to 30 days.
Interventions
OTHERVanicream Moisturizing Skin Cream
Vanicream Moisturizing Skin Cream daily application
OTHERVanicream Cleansing Soap
Vanicream Cleansing Soap daily use
Sponsors
University of Michigan
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Both groups, young and old, will receive the same intervention; therefore, single group study model was chosen.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Aged group (\>70 years old) * In good general health * Body mass index (BMI) preferably in the healthy range (approximately 25 kg/m2) and no greater than 30 kg/m2 * Fitzpatrick skin types I-V * Disrupted skin barrier defined as transepidermal water loss (TEWL) \>5 g/m2/h on the upper arms or \>3 g/m2/h on the buttocks * Clinical signs of skin dryness as determined by the investigator. * No disease states or physical conditions that would impair evaluation of the biopsy sites * Signed, written and witnessed informed consent form * Willing to comply with study procedures Young group (18-30 years old) * Good general health * BMI preferably in the healthy range (approximately 25 kg/m2) and no greater than 30 kg/m2 * Fitzpatrick skin types I-V * Disrupted skin barrier defined as transepidermal water loss (TEWL) \>5 g/m2/h on the upper arms or \>3 g/m2/h on the buttocks * Clinical signs of skin dryness as determined by the investigator * No disease states or physical conditions that would impair evaluation of the biopsy sites * Signed, written and witnessed informed consent form * Willing to comply with study procedures
Exclusion criteria
* Pregnant or lactating women or women contemplating pregnancy for the duration of the protocol (determined by self-report; if subjects are unsure of their pregnancy status, they will be excluded). * Frailty as determined by research study nurse * History of inflammatory skin conditions such as psoriasis or atopic dermatitis. * History of uncontrolled inflammatory or autoimmune disease. * History of keloids or any other condition that would complicate wound healing * History of allergic reactions to local lidocaine * Frequent nonsteroidal anti-inflammatory drug (NSAID) use (not including low dose aspirin) and unwilling/unable to discontinue NSAIDS for 2 weeks prior to enrollment to the end of the study. * Systemic steroids (excluding inhaled steroids for asthma) and unwilling/unable to discontinue systemic steroids for 3 weeks prior to enrollment to the end of the study. * Topical corticosteroid use within 2 weeks of enrollment. * Topical immunomodulation use such as calcineurin inhibitors within 2 weeks of enrollment * Other anti-inflammatory or immunodulatory medications (immunosuppression) * Received an experimental drug or used an experimental device 30 days prior to admission to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in skin hydration status in aged and young subjects | up to 30 days | Trans-epidermal water loss (TEWL) will be performed on the upper arm and buttocks at Visits 1 and 2. This instrument will measure the amount of water that is lost through the skin. The change in skin hydration status in each subject will be assessed and compared between groups. |
Countries
United States
Outcome results
None listed